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ABSTRACT

Bianco, Alexandra W. M.S., Purdue University, August 2015. Pharmacokinetics of
ketorolac tromethamine in horses after intravenous, intramuscular and oral single dose
administration. Major Professor: Sandra D. Taylor.
Non-steroidal anti-inflammatory drugs (NSAIDs) are an integral component of equine
analgesia, yet currently available NSAIDs are both limited in their analgesic efficacy and
have adverse effects. The NSAID ketorolac tromethamine (KT) is widely used in humans
as a potent morphine-sparing analgesic drug but has not been fully evaluated in horses.
The purpose of this study was to determine the pharmacokinetic profile of KT in horses
after intravenous (IV), intramuscular (IM), and oral (PO) administration. Nine healthy
adult horses received a single 0.5 mg/kg dose of KT via each route of administration.
Plasma was collected up to 48 h post-administration and analyzed for KT concentration
using HPLC-MS-MS. Non-compartmental analysis of IV dosage indicated a mean plasma
clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady
state of 0.77 L/kg. Non-compartmental analysis of IV, IM and PO dosages indicated mean
residence times of 2.0, 2.6, and 7.1 h, respectively. The drug was rapidly absorbed after
IM and PO administration and mean bioavailability was 71 and 57% for IM and PO
administration, respectively. Adverse effects were not observed after IV, IM and PO
administration. More studies are needed to evaluate the analgesic and anti-inflammatory
properties of KT in horses.
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CHAPTER 1.

INTRODUCTION

According to the United States Department of Agriculture 2012 census, there are
approximately 3.6 million horses currently living in the United States. The majority of
these horses are between the ages of 5-20 years old (56.7%).1 The most recent report on
equine morbidity in 1997 found that the leading causes of morbidity among adult horses
in the United States (as reported by horse owners) were injury/trauma (6.6%),
colic/gastrointestinal disease (5.6%), and lameness (4.8%).2 The leading causes of death
for horses older than 6 months of age in the United States in 2005 were “old age” (30.4%),
injury/trauma (16%), and colic (15.2%).3 While the specific diagnoses of horses who died
due to “old age” are unknown, a recent paper out of the United Kingdom found that
chronic lameness was the most common reason for horses over 15 years old to be
euthanized (24%).4 The role of horses in the United States has also evolved from primarily
being used for work to that of a companion animal, likely in response to agricultural
advancements. In 2005, 45% of horses in the United States were primarily classified as
used for pleasure, with 24.8% used for farm or ranch work.3
With the paradigm of horse ownership shifting, the field of equine veterinary care
has also shifted. One area of medicine in particular that has come to the forefront is the
recognition and management of animal pain.

While specific statistics on equine

veterinary care in the United States are lacking, it can be assumed that given the
demographic information on morbidity and mortality and the population of older, active
horses in the United States, it is likely that a horse will need veterinary care for a
potentially painful condition at some point in their lifetime.
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In horses, non-steroidal anti-inflammatory drugs (NSAIDs) are the primary focus
of pain research as they are the mainstay of equine analgesic therapy. However, there are
few NSAIDs currently used in horses, and the same drugs and dosages are used for a
variety of conditions ranging from minor injury to major abdominal or orthopedic surgery.
Given these limitations, NSAIDs are not always sufficient at providing adequate analgesia
in certain patients. In order to increase patient comfort, adjunctive analgesic drugs such
as opioids or lidocaine are used. However, the side effects and/or limitations of these
drugs may negate their use, resulting in animals continuing to experience pain.
Ketorolac tromethamine (KT) is a NSAID that was approved for short-term
analgesia in humans in 1989. Since its approval, KT has been widely used in human
medicine primarily as a post-operative analgesic for moderate to severe pain. Though only
labeled for oral (PO) and intramuscular (IM) use in humans, KT is also used intravenously
(IV) or as a constant rate infusion (CRI). Numerous studies in human medicine have
evaluated KT as a morphine-sparing analgesic in post-operative patients and
demonstrated significant reduction in morphine consumption (22-44%) when patients
were concurrently treated with KT for the first 24 hours following abdominal or
orthopedic surgery versus morphine analgesia alone.5-10
Though KT is commonly used as a potent analgesic in human medicine, there has
been little research regarding its use in animals. A single dose pharmacokinetic profile of
KT has been evaluated in dogs,11,12 cats,13 sheep,14 calves,15 and goats.16 While there
have also been two publications regarding the pharmacokinetics of KT in horses, the first
was in 1994 and the horses in the study only received a single 300 mg IV or IM dose
without a randomized crossover design.17 The second, in 2014, examined the
pharmacokinetics of KT when given IV to colts undergoing general anesthesia with
concurrent administration of multiple other drugs.18
The goal of the research performed for this thesis was to better characterize the
pharmacokinetic profile of KT in the horse in order to lay the foundation for future clinical
use of the drug. Specifically, the aims of the study were to establish the pharmacokinetic
profile of KT in the horse after a single IV, IM, and PO dose, establish the bioavailability of
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KT when delivered IM or PO, and to document any adverse effects noted after a single IV,
IM or PO dose of KT in the horse.
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CHAPTER 2.

2.1

LITERATURE REVIEW

Assessing Pain in Horses

Whether or not animals experience pain is a surprisingly difficult question to answer
in an objective way and one that has been historically debated. Early research models
designed to detect pain in animals largely consisted of assessment of withdrawal
response to noxious stimuli, or nociception. Nociception refers to the complex neural
pathways that serve to preserve the life of the animal by preventing physical damage to
the tissues.
Because nociception lacks an emotional component, it can be argued that response
to noxious stimuli does not correlate to pain, as “pain” refers to the actual feeling of
suffering. With this definition of pain, it was historically argued that animals could not
experience pain as they lack the ability to communicate the feeling of suffering. Once it
was accepted that even humans that cannot communicate verbally (e.g. infants) can
clearly experience pain and suffering, more focus was given as to how to recognize pain
in those who lack the ability to communicate. This has been a crucial turning point in the
area of animal research, and current research has focused on how physical suffering can
be better recognized in both animals used as research subjects and in veterinary patients.
Prey species, such as horses, provide an even greater challenge in pain recognition due to
the natural disadvantage of displaying pain as it implies vulnerability.1,2
In addition to nociceptive responses that are the rudimentary signals of pain,
animals have been shown to exhibit more advanced pain responses that reflect cognitive
function, such as the ability to anticipate physical discomfort. A familiar example of this is
when an animal is confronted with an action, object, location, or person that previously
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caused pain or discomfort and displays aversive or even aggressive behavior to avoid
repetition of an unpleasant experience.1,2
As reactive or aversive behaviors are evolutionarily beneficial to the survival of an
animal, they do not necessarily support a conscious feeling of suffering that goes beyond
simple instinct. Regardless of the emotional depth of animal pain, however, it is generally
accepted by the veterinary community that animals experience physical suffering and
benefit from analgesic therapies.
Given the need for objectivity in assessing animal pain, several pain scales have
been developed for use in horses in the past decade. One challenge, however, is that
there is no “gold standard,” and animal pain scales are typically validated with physical
and behavioral parameters correlating mainly to the sympathetic nervous system and
hypothalamic-pituitary-adrenal axis.3-7 This validation is less than ideal, as observer bias
and concurrent illness may influence behavioral and physical data. Furthermore, it has
been demonstrated that breed and personality are closely related to the expression of
pain in horses,8 a factor that can be confounding when clinical cases are compared with
scoring systems.
Even when using a standardized method, relying on subjective human
interpretation of animal pain is difficult. This was demonstrated in a 2012 clinical trial in
which owners of dogs with hip osteoarthritis were asked to evaluate the clinical response
to treatment with a given analgesic drug. The results indicated a clear placebo effect for
all outcome variables of efficacy.9

2.2

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Non-steroidal anti-inflammatory drugs (NSAIDs) exert their anti-inflammatory
effects via inhibition of cyclooxygenase (COX) enzymes in the arachidonic acid pathway.
The activity of COX enzymes are rate-limiting steps of the cascade; therefore COX
inhibition effectively reduces the conversion of arachidonic acid into several families of
eicosanoids, including prostaglandins, prostacyclins, and thromboxane.
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Tissue expression of COX and the products of the arachidonic acid pathway are
integral to the healthy function of many biologic processes within the body, including
maintenance of the immune system, gastrointestinal tract, reproductive tract,
cardiovascular system, and renal system.10
While there are three isoforms of the COX enzyme, two are of interest in drug
therapy: COX-1 and COX-2. The 3rd, COX-3, has not been evaluated in horses but its
significance is debated in humans.10 The COX-1 isoform is expressed throughout the body
and plays a vital role in maintaining the integrity of mucosal tissue through production of
prostaglandins. These prostaglandins, namely prostaglandin E2 (PGE2), are involved in the
regulation of gastric acid and mucous production in the stomach, and local vasodilation
to the stomach and kidney to maintain adequate blood flow. Thromboxane A2 is also an
important product of COX-1 activity and is involved in inhibition of platelet
aggregation.10,11
The COX-2 isoform is also constitutively expressed by select tissues throughout the
body. While expression of COX-2 also leads to increased production of prostanoids such
as PGE2, it is thought to more specifically promote the inflammatory functions of PGE2.10
In horses, low-level expression of COX-2 has been demonstrated in healthy tissues
including the glandular mucosa of the stomach,12,13 mucosa of the urinary bladder,13
jejunum14,15 and left dorsal colon.16 Higher COX-2 expression in these tissues is likely
beneficial as PGE2 promotes local inflammation and is protective in its inhibition of
cytotoxic immune response to pathogen entry.17
In states of inflammation, global COX-2 expression is up-regulated by growth
factors and inflammatory mediators such as interleukin-1 (IL-1), tumor necrosis factor
alpha (TNF-α) and lipopolysaccharide (LPS).18 In horses, increased COX-2 expression has
been demonstrated in cases of gastric ulceration of both the glandular and squamous
portions of the stomach12,19 as well as after ischemia and reperfusion injury to the colon16
and jejunum.14 Increased COX-2 expression has also been demonstrated in the laminar
cells of horses after induction of laminitis using the black walnut extract model. 20
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Non-steroidal anti-inflammatory drugs are analgesic, anti-inflammatory, and antipyretic primarily due to inhibition of prostanoid production. Prostanoids reduce the
activation threshold of sodium channels on sensory neurons, effectively producing an
hyperalgesic effect.10 When vascular endothelial cells are exposed to pyrogens such as
LPS, PGE2 is released, activating the hypothalamus and inducing subsequent
hyperthermia. With inhibition of PGE2, NSAIDs therefore act as anti-pyretic drugs.
Given the role of COX enzymes in the pathways of pain and inflammation, NSAIDs,
or COX inhibitors, are highly effective drugs in alleviating pain in both humans and
animals. Furthermore, unlike sedatives or opioids that simply dull the transmission of
pain, NSAIDs actually reduce inflammation and the underlying cause of discomfort.
2.3

Adverse Effects and COX Selectivity

As NSAIDs target the same mechanisms which in health are protective, NSAID use
may lead to unwanted adverse effects, namely to the gastrointestinal and renal systems.
As in other species, there is a risk of adverse effects (AE) when using NSAIDs in horses.
Several studies have compared the relative risk of AE between different NSAIDs.
A study by MacAllister et al. in 1993 was one of the first to compare the risk of
adverse effects between nonselective NSAIDs in healthy adult horses (n=16). In this study,
horses either received the label dose of phenylbutazone (4.4 mg/kg), flunixin meglumine
(1.1 mg/kg), ketoprofen (2.2 mg/kg), or saline, IV every 8 hours for 12 days. Postmortem
examination revealed histologic erosions of the glandular mucosa of the stomach in all
but one of the NSAID-treated horses. A treatment effect of phenylbutazone was
negatively correlated to total protein and albumin levels, and only horses that received
phenylbutazone had evidence of renal papillary necrosis or intestinal (non-gastric)
lesions. With the clinicopathologic and histologic grading of this study, the adverse effects
were most severe after treatment with phenylbutazone, followed by flunixin meglumine
and ketoprofen, respectively.21
A more recent study by Mozaffari et al. in 2013 employed the same basic design as
MacAllister and examined the same drugs in apparently healthy donkeys (n=20). In this
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study, the phenylbutazone, flunixin meglumine, and ketoprofen were administered at 4.4
mg/kg, 1.0 mg/kg, 2.2 mg/kg, respectively, IV every 12 hours. During the course of
treatment, the liver enzymes of all NSAID-treated animals significantly increased, and
there was a significant increase in creatinine of phenylbutazone-treated animals. At postmortem exam, all NSAID treated donkeys had ulcerations of the glandular mucosa of the
stomach as well has histopathologic changes to the liver and kidney. While all NSAIDs
were documented to have adverse effects, the results echoed MacAllister et al. in ranking
of severity of adverse effects from phenylbutazone being most severe followed by flunixin
meglumine and ketoprofen.22
In horses, the severity of adverse effects when comparing different NSAIDs has also
correlated to the dosage of the NSAIDs. As COX inhibition is known to be dose-dependent,
the difference in severity of adverse effects may be related to the relative potency of each
drug. If a drug lacks potency, a larger amount of drug is needed to produce the desired
effect and may increase the severity of adverse effects.
Recently, in both human and animal medicine, there has been a focus on COXselective NSAIDs, with the idea that selective inhibition of COX-2 would result in less
adverse effects due to the maintenance of COX-1 activity. However, while COX-1 has a
vital role in maintaining integrity of the gastrointestinal tract, selective inhibition of COX2 would not spare potential toxicity to the kidneys or liver as both COX-1 and COX-2 are
important in maintenance of blood flow.23 This has been demonstrated in horses in a 2014
study where phenylbutazone, a nonselective COX inhibitor, and meloxicam, a COX-2
selective inhibitor, were found to have similar risk of adverse effects in volume-depleted
horses.24
In humans, the COX-2 specific NSAIDs have been shown to be as effective as nonselective NSAIDs at analgesia, with little change in risk of adverse effects.25 However, few
analgesic trials in human medicine evaluate patients receiving NSAIDs alone without the
addition of supplemental narcotics.
There have been very few, if any, randomized controlled trials that compare the
safety and efficacy of COX-2 vs. nonselective COX inhibitors in clinical equine patients.26,27
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Several experimental studies have compared the nonselective COX inhibitor
phenylbutazone to the COX-2 selective NSAID meloxicam and found evidence of adverse
gastrointestinal and renal effects when phenylbutazone was used at the recommended
label dose, but also when meloxicam was used at greater than the recommended 0.6
mg/kg every 24 hours for a 14-day period.28,29
There has been some question that NSAID use can affect not only the mucosal
healing of the gastrointestinal tract but also motility. This is especially relevant in horses
given the widespread use of NSAID therapy after major abdominal surgery in horses and
the consequences of post-operative ileus.30 In the ischemia-reperfusion model of equine
colic, transepithelial electrical resistance (TER) is used to assess recovery of intestinal
barrier function. A decreased TER is expected after ischemic damage as there is increase
permeability of sodium and chloride ions; TER should increase as the intestine heals.
Flunixin meglumine has been found to prevent increases in TER after ischemic damage to
the jejunum and potentially may inhibit intestinal recovery in cases of ischemia and
reperfusion.31,32 In comparison to the nonselective flunixin meglumine, the COX-2 specific
deracoxib had similar results,31 whereas meloxicam did not prevent TER increase.32
A 2009 study by Menozzi et al. used electrical field stimulation to test the effects of
non-selective NSAIDs (indomethacin, flunixin meglumine) vs. COX-2 selective (celecoxib)
on motility on postmortem equine ileal samples. Results of this study indicated that
nonselective NSAIDs had minimal effects on tonic and phasic contractions of samples,
while COX-2 selective inhibition was associated with concentration-dependent effects on
both tonic and phasic motility.33

2.4

Adjunctive Therapy

2.4.1 Opiates
Adjunct medications such as opiates or local anesthetics (e.g. lidocaine) are often
used in conjunction with NSAIDs to provide additional pain control when NSAIDs alone
are insufficient. In humans, narcotic analgesia, such as morphine sulfate delivered by a
patient-controlled analgesia device, is frequently employed during the immediate post-
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operative period following orthopedic and soft tissue procedures, with or without
concurrent NSAID use.34
Given their place in human analgesic therapy, opioids have also been evaluated
for their analgesic properties in horses with mixed results. In experimental pain models
of single-dose analgesic efficacy, opiates have shown varying degrees of analgesia in
horses and are complicated by potentially confounding sedative effects.35,36 In a model of
LPS-induced carpal synovitis in the horse, continuous morphine or methadone infusion
produced analgesic effects while infusions of butorphanol or tramadol were ineffective
at analgesia.37
There have been few clinical trials evaluating the use of opiates as analgesics in
horses. In 2004, Sellon et al. reported less surgical stress, more normal behavior, reduced
weight loss and quicker recovery in horses treated with a combination of flunixin
meglumine and butorphanol in clinical patients following colic surgery compared to
control horses treated with flunixin meglumine alone.38
Regardless of their potential analgesic effects, opiates have well established
effects on behavior and gastrointestinal motility. Reported behavioral effects of opiates
in horses include restlessness, increased appetite, ataxia, head tossing, and increased
locomotion.35,39 The negative effects of opiate therapy on gastrointestinal motility are
also well documented in the equine patient and may contraindicate their use in high-risk
patients regardless of degree of perceived pain.38- 41

2.4.2 Lidocaine
In two human meta-analyses of 22 randomized controlled trials including over 850
post-operative human patients, IV lidocaine was associated with decreased opiate use,
improved pain scores, and reduced incidence of nausea and vomiting.42,43 Similar results
have been found in horses; in cases of postoperative colic, lidocaine use was significantly
associated with decreased incidence of ileus as well as an increase in short term survival.44
A 2005 study evaluated the anti-nociceptive properties of lidocaine using models
of thermal pain as well as duodenal and colorectal distension. When delivered as a CRI,

12
lidocaine was effective at increasing the pain threshold to thermal stimulation; however,
lidocaine failed to significantly alter tolerance to colorectal distension.45
Interestingly, both flunixin meglumine and lidocaine have been shown to increase
neutrophil migration and adhesion in vitro.46 In an in vivo model of ischemia and
reperfusion injury to the jejunum meant to mimic equine colic, immunohistochemistry
demonstrated a significant increase in jejunal neutrophils 18 hours after ischemia in
horses treated with flunixin meglumine compared to saline controls.15 Treatment with
lidocaine alone or a combination of lidocaine and flunixin meglumine dampened this
increase in neutrophils.15 While this was an in vivo model of equine gastrointestinal
disease, all horses received perioperative butorphanol and no discussion was given as to
analgesic efficacy of lidocaine when used alone or in combination with flunixin meglumine.

2.5

Current Analgesic Drugs are Limited

Given their unique ability to treat both pain and inflammation, NSAIDs play an
integral role in equine drug therapy, and continued research and refinement is warranted.
There are currently only three NSAIDs specifically labeled for systemic use in horses in the
United States: phenylbutazone, flunixin meglumine, and firocoxib. These medications are
used at the labeled dosages to treat a variety of conditions ranging from those associated
with a mild degree of discomfort (e.g. lacerations, soft tissue injury, corneal ulcer, chronic
osteoarthritis) to those assumed to have a larger potential for suffering (e.g. fracture,
abdominal or orthopedic surgery, laminitis).
While the pharmacokinetics and safety of different NSAIDs have been established
in horses, there have been few randomized controlled studies that have specifically
focused on the analgesic potency and efficacy of NSAIDs in the treatment of acutely
painful conditions. A reversible model of equine lameness has been developed by
Foreman et al. and has been used to assess the analgesic efficacy of flunixin meglumine
and phenylbutazone after induction of lameness. Using this method, flunixin meglumine
or phenylbutazone at the label dose (1.1 mg/kg IV and 4.4 mg/kg IV, respectively) have
been shown to effectively reduce heart rate and lameness score in horses up to 4 hours
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post administration.47,48,49 There is one randomized, controlled, trial that compared the
analgesic efficacy of two NSAIDs in horses experiencing moderate-severe pain. Naylor et
al. in 2014 compared the efficacy of flunixin meglumine (1.1 mg/kg IV every 12 hours) or
meloxicam (0.6 mg/kg IV every 12 hours) in 60 horses undergoing abdominal surgery for
a strangulating small intestinal lesion. While there was no difference of treatment on
horse survival, post-operative pain scores were significantly higher in horses who received
meloxicam.50 While not significant between treatments, 58 of the 60 horses also received
lidocaine as a CRI.
The recognition of pain is an active area of research in equine medicine, especially
in regards to outcome following gastrointestinal surgery. In 2005, a retrospective study
was performed using 300 cases of surgical colic evaluated with a simple behavioral pain
score. Results of this study indicated 81/253 (32.1%) of all horses experienced
postoperative pain in, including 53/123 (43.1%) of horses with small intestinal lesions.51,52
Furthermore, the authors reported that post-operative pain following colic surgery was
the most common reason for euthanasia. Though not specified, it is presumed that NSAID
therapy was used in the immediate postoperative period as it is considered standard of
care after colic surgery.
Using a multi-dimensional pain scale based on physiological and behavioral
parameters, termed the post abdominal surgery pain assessment scale (PASPAS),
Graubner et al. in 2011 demonstrated that in 34 cases of surgical colic, 35.3% of horses
demonstrated low pain, 38.2% moderate pain, and 26.5% severe pain at 8 hours following
surgery.53 The majority of horses retained at least a low level of pain for at least 24 hours
postoperatively. The horses in this study all received flunixin meglumine at 0.5 mg/kg
every 4 hours IV immediately following surgery. Lidocaine CRI was used as deemed
necessary, though these cases were not differentiated in the results.
One recent study utilized two behavior-based pain scoring systems to assess
horses after surgery for gastrointestinal disease. Forty-eight horses were followed over
3 days post-operatively, during which time they received standard of care analgesic
therapy consisting of flunixin meglumine (1.1 mg/kg IV every 12-24 hours) and lidocaine
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infusions as deemed necessary. In this population, pain scores using both scoring systems
were significantly and consistently higher in non-survivors (9/48) vs. survivors (39/48);
however, all animals experienced some degree of postoperative pain.7
The use of facial expression as an indicator of pain has also been recently
examined in horses when the “Horse Grimace Scale” was compared to a Composite Pain
Score system. While it was found that the two pain scales were highly correlated to each
other, it was also evident that horses undergoing routine castration experienced pain
postoperatively. Furthermore, there was no difference in pain scores of horses who
received a single perioperative dose of flunixin meglumine (1.1 mg/kg IV) or those who
received an additional dose postoperatively.5
Despite the recent focus on pain recognition, there has been little discussion on
the fact that many horses continue to experience pain despite “standard-of-care”
analgesic therapy postoperatively. Current therapy primarily consists of a NSAID with
adjunctive opioid or lidocaine use as deemed indicated by the attending veterinarian.
There is a need for a potent analgesic that can be safely administered to equine
patients in situations associated with high degrees of pain, such as following orthopedic
or abdominal surgery.

2.6

Ketorolac Tromethamine

2.6.1 Overview
Ketorolac tromethamine (KT) is a pyrrolizine carboxylic acid derivative, nonselective cyclooxygenase inhibitor that is administered clinically in its tromethamine salt
form.54,55 The drug is actually a racemic mix of (S) and (R) enantiomers, with the (S) form
being pharmacologically active.56
Since its approval for use in humans in 1989, KT has been widely used in human
medicine primarily as a post-operative analgesic for moderate to severe pain, though like
other NSAIDs it is anti-inflammatory and anti-pyretic.55,57,58 Though only labeled for oral
and intramuscular use, KT is often used IV or as a CRI.59-64
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Ketorolac, like other NSAIDs, indirectly causes analgesia by dampening the
hyperasthetic effect of prostaglandins. This means that KT does not alter pain responses
in non-inflamed tissues, unlike a centrally-acting narcotic analgesic such as
morphine.54,55,57,65 Because it is ineffective in a non-inflamed state, KT is non habitforming; while this is typically not a concern for veterinary patients, it becomes relevant
when considering the humans involved in veterinary care.

2.6.2 Metabolism and Excretion
Ketorolac conjugation with glucuronide is a major metabolic pathway in the
human, monkey, and mouse and is thought to occur in the kidney, as conjugates have
been detected in the urine but not the plasma.66 Metabolites of KT do not have any
analgesic activity.57 In humans, monkeys, and rabbits, KT has been shown to be primarily
excreted in the urine, whereas mice and rats have a higher percentage of fecal
excretion.66

2.6.3 Analgesic Efficacy of Ketorolac Tromethamine
Because KT is a non-specific COX inhibitor, the drug induces analgesia by the same
mechanism as other NSAIDs. However, KT has been shown to have increased analgesic
potency, or the relative amount of drug needed to exert a physiological or clinical
response relative to other NSAIDs.54,65 While it is not known why KT is more potent than
other NSAIDs, it may be due to its low distribution into adipose tissue.66,67
Initial analgesic evaluations consisted of established rodent laboratory tests
performed by a pharmaceutical laboratory for the purpose of drug approval. In the
writhing model for visceral pain, mice receive an intraperitoneal injection of a chemical
irritant (such as phenylquinone) and are assessed for “writhing,” or specific abdominal
contraction and hind leg extension.68 When administered orally, ketorolac was found to
be over 350 times more potent than aspirin and phenylbutazone using a phenylquinoneinduced writhing model in mice.54,65 In rats, ketorolac has been shown to have
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significantly greater potency in reducing writhing than celecoxib, a COX-2 specific
NSAID.67
One common animal model of inflammation-induced pain is the carrageenaninduced model of paw edema. In this model, carrageenan yeast is injected in the plantar
aspect of a hind rat paw to induce inflammation and pain; response is measured by time
until foot withdrawal or escape after application of pressure.69 After pre-treatment with
oral ketorolac, rats have been shown to exhibit a dose-dependent increase in pain
threshold of the affected paw.54,67 Importantly, there was no change in pain threshold of
the non-inflamed paw, supporting a lack of central activity.
A lack of central activity was supported by an additional animal model of
analgesia, the hot-plate method, in which mice are assessed for tolerance to heat before
and after drug administration. Importantly, this method does not induce inflammation;
therefore, NSAID administration should have little effect using this model. When tested,
an intraperitoneal injection of ketorolac did not alter the response of mice using this
method, whereas administration of morphine did have a significant effect.54

2.6.4 Anti-Inflammatory Efficacy of Ketorolac
Ketorolac has been shown in vitro to exhibit dose-dependent inhibition of
neutrophil

chemotaxis,

adherence,

and

degranulation

with

release

of

myeloperoxidase.70,71
Using the carrageenan-induced model of inflammation described in section 1.6.3,
the inflamed and uninflamed paws are compared for degree of inflammation as
determined by comparing the weight of equal sized punch biopsies from both back feet.66
In rats pre-treated with NSAIDs, the potency of KT was 36 times that of phenylbutazone
and 3 times as potent naproxen at reducing paw edema.54,65
One study evaluated the anti-inflammatory effects of ketorolac using a model of
pulmonary embolism in the rat. In this model, ketorolac was shown to inhibit the
upregulation of COX-2 as well as expression of the adhesion molecules intracellular
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adhesion molecule-1 and selectin E. Ketorolac was also associated with significant
reduction in cardiac tissue myeloperoxidase.71
In one of the first studies of ketorolac in non-laboratory animals, ketorolac was
evaluated for its ability to ameliorate clinical and physiologic responses to LPS infusion in
calves. In this study, KT (1.1 mg/kg IV) was compared to the other nonselective NSAIDs
flunixin meglumine (1.1 mg/kg IV) and ketoprofen (2.2 mg/kg IV). All three NSAIDs were
equally effective at reducing the clinical signs of endotoxemia as well as preventing
increases in thromboxane A2 and prostacyclin.72 In dogs, ketorolac has also been
demonstrated to significantly reduce plasma PGE2 levels for at least 24 hours after a single
0.5 mg/kg IV dose.73

2.6.5 Safety
As stated in section 1.3, NSAID use in all species is associated with potential
gastrointestinal, renal, or coagulation side effects due to the inhibition of COX-1. The
safety of ketorolac has been evaluated extensively in humans with mixed results. While
several studies report that the risk of adverse effects is not higher than other NSAIDs,35,74
other studies have cited KT has having a higher relative risk of upper gastrointestinal
bleeding in comparison to other human NSAIDs.75 The risk of adverse effects in humans
has been shown to be increased in certain patients with preexisting conditions such as
renal or gastrointestinal disease, coagulopathy, or those receiving concurrent
administration of other NSAIDs. Given these potential risks in the human population, use
of KT in the United States is restricted to no more than 5 days of treatment. 76

2.7

Clinical Trials of Ketorolac Tromethamine in Humans

Early studies in rats and mice indicated that the 50% inhibitory dose (ID50) at which
KT is analgesic is 0.1-0.3 mg/kg vs. ≥0.3 mg/kg for anti-inflammatory effects.65 Given the
analgesic potency of ketorolac, it is primarily used in human medicine for its analgesic
rather than its anti-inflammatory effects.

18
There have been very few randomized controlled trials that have directly
compared KT to other NSAIDs without the confounding use of opioids. Two studies have
compared a single dose of oral ibuprofen or intramuscular KT in an emergency room
setting. In both studies, the drugs were equal in efficacy, though neither provided
complete analgesia.77,78 However, patients were only monitored for 2 hours, and the
recorded pain intensity scores had not yet plateaued. In another study utilizing
emergency room patients, KT was shown to be equally effective as acetaminophen at
reducing fever.79
The vast majority of randomized controlled clinical trials in humans have been
regarding the efficacy of KT as a “morphine-sparing” analgesic, especially in postoperative patients using patient-controlled analgesia systems with the ability to selfadminister morphine. The results of these studies showed significant reduction in
morphine consumption (22-44%) when patients were concurrently treated with KT for
the first 24 hours following abdominal or orthopedic surgery vs. morphine analgesia
alone.34,59,60,61,80,81
The ability of KT to reduce opioid use is significant in humans as it results in fewer
opioid-related adverse. In a randomized controlled clinical trial, oral KT was compared to
acetaminophen-codeine in terms of efficacy and incidence of adverse effects in 123
patients presenting to the emergency room for acute back pain. The patients were
instructed to take the medication as needed every 4-6 hours for 1 week. Results indicated
that while both drugs were effective analgesics, patients receiving acetaminophencodeine had significantly greater incidence of adverse effects and were more likely to
drop out of the trial than those receiving KT.58 In a 2012 meta-analysis, a single
preoperative dose of KT demonstrated not only a positive effect on reduction of
postoperative pain, but also a decrease in incidence of nausea and vomiting.82
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2.8

Ketorolac Tromethamine in Veterinary Species

2.8.1 Pharmacokinetics
The single dose pharmacokinetic profile of KT has been evaluated in dogs,83,84 cats,85
sheep,86 calves,87 and goats88 (Table 1-1). In non-anesthetized dogs, Pasloske et al. in 2002
found KT to have a similar pharmacokinetic profile to that in humans when administered
IV or PO at a dose of 0.5 mg/kg. The oral bioavailability of KT was variable. The authors
recommend a dosing regimen of 0.5 mg/kg every 8 hours in dogs.83 In a more recent
study, the pharmacokinetics of a single IV dose of KT was examined in dogs undergoing
routine castration under general anesthesia.84 In these dogs, drug clearance was similar
to that found by Pasloske et al., but the V(dss) was markedly increased, resulting in an
elimination half-life (t1/2) of approximately 10 hours rather than the 4 hours found in
conscious dogs.83,84
In cats, the single dose pharmacokinetic profile of KT was determined after a 0.5
mg/kg IV dose was given 20 minutes prior to general anesthesia and either a neuter or
ovariohysterectomy. The pharmacokinetic profile was similar to that in conscious dogs
and humans, with a t1/2 of approximately 4 hours.85
Pharmacokinetic evaluation of KT in ruminants has been performed using higher
drug dosages than those used in humans and simple stomached animals. In goats, calves,
and sheep, each animal received a single intravenous (2 mg/kg) dose. Goats and calves
were also given KT orally (2 mg/kg in goats, 8 mg/kg in calves), and sheep received an
additional dose IM (2 mg/kg). Overall, the clearance of KT was found to be much greater
in sheep and goats, with serum t1/2 of 0.4 and 1.05 hours, respectively.86,88 The serum t1/2
in calves was found to be similar to that in dogs and humans, at 5.9 hours.87 The difference
in clearance rates are thought to be due to differences in protein binding.
There have been two publications regarding the pharmacokinetics of ketorolac in
horses. Plånborg, et al. in 1994 described the pharmacokinetic profile of ketorolac in the
horse; however, the horses in the study only received a single 300 mg IV or IM dose
without a randomized crossover design.89 Furthermore, the authors acknowledged the
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need for further pharmacokinetic evaluation. In a 2014 study, Ferraresi et al. assessed the
pharmacokinetics of a single perioperative dose of ketorolac (0.5 mg/kg IV) before routine
castration in colts. These horses were also under general anesthesia and results indicated
a short t1/2 in horses of approximately 40 minutes.90

2.8.2 Clinical Trials
Despite widespread use of ketorolac as an analgesic in human medicine, there has
been little research regarding its clinical use in animals. Mathews et al. in 1996 is currently
the only randomized controlled study investigating use of ketorolac in clinical veterinary
use. In this study, ketorolac was compared to flunixin meglumine, butorphanol and
oxymorphone after exploratory laparotomy and shoulder arthrotomy in dogs. The results
of this randomized controlled trial found that ketorolac given at a dose of 0.5 mg/kg IM
was as effective as flunixin meglumine and superior to both butorphanol and
oxymorphone in providing consistent post-operative analgesia.91

Table 2-1: Various pharmacokinetic parameters of different species after a single dose of ketorolac tromethamine
Author

Year

Species

Number
of
Animals

Nagilla

2007

Calf

5

IV

-

-

2

Nagilla

2008

Calf

5

-

-

PO

8

5.2 ± 3.0

Villa

2015

Cat

12

IV

-

-

0.5

3.1 ± 1.04

Pasloske

1999

Dog

6

IV

-

-

0.5

Route of
Administration

Dose
(mg/kg)

Cmax
(ug/mL)

t1/2 (hour)

Vd (L/kg)

Cl
(ml/kg/min)

5.86

0.2 ± 0.074

0.79 ± 0.61

F (%)

MRT
(hour)
8.4 ± 8.2

86.5 ± 20.6
4.14 ± 1.18

0.18 ± 0.06

0.95

4.55

0.33 ± 0.1

1.3 ± 1.1

6.47 ± 2.86

98.7

98.9

Pasloske

2000

Dog

6

-

-

PO

0.5

1.6 ± 0.3

4.07

Cagnardi

2013

Dog

10

IV

-

-

0.5

2.5 ± 1.1

10.9

1.03 ± 0.62

1.5 ± 1.4

5.6 ± 2.1

Nagilla

2008

Goat

5

IV

-

-

2

1.05

0.42 ± 0.42

8.7 ± 3.9

0.86 ± 0.68

0.73 ± 0.59

Protein
binding
(%)

100.9 ± 46.7

Nagilla

2008

Goat

5

-

-

PO

6

Plånborg

1994

Horse

3

IV

-

-

0.5

34

Plånborg

1994

Horse

3

-

IM

-

0.5

Ferraresi

2014

Horse

6

IV

-

-

0.5

4.74 ± 5.38

0.69 ± 0.61

0.21 ± 0.13

5.5 ± 2.2

Jung

1988

Human

15

IV

-

-

10 mg

2.39 ± 1.3

5.09 ± 2.01

0.11 ± 0.02

0.35 ± 0.07

Jung

1988

Human

15

-

IM

-

10 mg

0.77 ± 0.12

4.99 ± 1.88

108.7 ±22.3

6.27 ± 1.12

Jung

1988

Human

15

-

-

PO

10 mg

0.81 ± 0.25

5.07 ± 0.97

100.0 ± 19.8

6.32 ± 1.06

Santos

2001

Sheep

5

IV

-

-

2

0.3 ± 0.15

0.25 (0.08)

12.4 ± 2.8

Santos

2001

Sheep

5

-

IM

-

2

4.1 (1.07)

0.25 ± 0.05

0.31 (0.10)

13.3 ± 1.3

6.7

6.8 ± 3.07
0.28

132 ± 23.2

2

44.8 ± 11.3
1.95

69
75.8 ± 2.9
5.34 ± 1.02

0.37 ± 0.18
97.6 ± 10.15

0.5 ± 0.15
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3.2

Introduction

Pain management is an active area of investigation in veterinary medicine.
Managing pain in equine patients relies primarily on drug intervention, as other aspects
of multimodal therapy are often impractical or cost-prohibitive. Non-steroidal antiinflammatory drugs (NSAIDs) are an integral component of equine pain management as
they demonstrate both anti-inflammatory and analgesic effects. The currently available
NSAIDs labeled for use in horses are used to treat a wide variety of conditions associated
with varying degrees of pain. Despite standard analgesic therapy, horses may still
experience moderate to severe pain associated with certain conditions such as acute
laminitis or following surgery. In a recent evaluation of 34 horses undergoing exploratory
laparotomy, 65% of horses experienced moderate to severe pain following surgery
despite “standard of care” analgesic therapy.1 The horses in the Graubner et al. study
received flunixin meglumine (0.5 mg/kg IV) every 8 hours and were evaluated for pain
using a multidimensional pain scoring system based on physiological and behavioral
parameters. In a retrospective study of 300 equine cases of surgical colic, post-operative
pain was reported in 32% of horses that received flunixin meglumine (0.25 mg/kg IV)
every 8 h after recovery from anesthesia.2 Pain was the most common reason recorded
for euthanasia in these horses.2 Opiate drugs, such as morphine and butorphanol, have
been used to provide adjunctive analgesia in horses receiving NSAIDs;3 however, their use
is associated with significant side effects in horses including behavior changes and
gastrointestinal hypomotility that often limit their use in high-risk patients, regardless of
pain score.3-5
Ketorolac tromethamine (KT) is a pyrrolizine carboxylic acid derivative NSAID and
non-selective cyclooxygenase (COX) inhibitor. While it is widely used in human medicine,
primarily as a post-operative analgesic for moderate to severe pain, KT has not been
thoroughly evaluated in horses6-12 Ketorolac tromethamine is commonly administered
intravenously (IV) or as a constant rate infusion (CRI) in humans, even though it is labeled
for intramuscular (IM) and oral (PO) use6-8 Numerous studies in human medicine have
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evaluated KT as a morphine-sparing analgesic in post-operative patients. The results of
these studies indicated a 22 to 44% reduction in morphine consumption when patients
were treated with morphine and ketorolac for the first 24 h following abdominal or
orthopedic surgery versus morphine alone6,7,10 The adverse effects of KT in humans are
similar to those associated with all NSAIDs, including gastrointestinal ulceration and
increased risk of bleeding, but the overall incidence of adverse effects in post-operative
patients is low.13 Ketorolac tromethamine has been shown to be equivalent in safety to
the NSAIDs diclofenac and ketoprofen in post-operative human patients14 In rats, KT has
demonstrated an anti-inflammatory potency up to 50 times that of phenylbutazone, and
anti-pyretic properties 20 times that of aspirin.9 When administered orally in mice, KT was
found to be more than 350 times as potent as phenylbutazone with respect to
analgesia.9,15 Studies in mice and rats have indicated that the relative analgesic potency
of KT is even greater than its anti-inflammatory potency.9,15
We are aware of only two studies that have investigated the pharmacokinetic
profile of KT in adult horses. A 1994 study reported pharmacokinetic data after a single
300 mg IV or IM dose of KT in six adult horses,11 but the study failed to account for
individual horse variability as it was not a crossover design. A more recent study evaluated
KT in 6 colts (0.5 mg/kg IV) undergoing castration.12 The colts in that study received
several other medications concurrently and underwent general anesthesia, two factors
that have the potential for confounding kinetic data as it is unknown how drug
interactions or anesthesia affect metabolism of KT in the horse. The objective of the study
reported here was therefore to evaluate the pharmacokinetic profile of KT in healthy
adult horses after IV, IM, and PO single dose administration, and to investigate the
potential for adverse effects following KT administration. A single dosage of 0.5 mg/kg
was selected for investigation based on extrapolation from recommended human dosage
protocols and previous pharmacokinetic studies in the horse and dog.11,16-18
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3.3

Materials and Methods

3.3.1 Animals and Experimental Design
Nine adult horses from the Purdue University teaching herd were utilized for the
crossover pharmacokinetic study. The horses were determined to be healthy on the basis
of physical examination, complete blood count (CBC) and serum biochemical analysis
(SBA), and had no history of NSAID administration within two months prior to the start of
the study. A repeated Latin square design was used to ensure that each horse received
each route of drug administration (IV, IM, and PO). Horses were randomly assigned a
number (1 through 9) and divided into groups of 3, and each trial was staggered over the
course of 3 days. The first route of administration was randomly assigned to each horse.
The horses consisted of 6 mares and 3 geldings that ranged in age from 6 to 24 years old,
with a mean of 15 ± 6 years. Five breeds were represented, including 3 Standardbreds, 2
Thoroughbreds, 2 Warmbloods, 1 Saddlebred and 1 Quarter Horse. The horses weighed
460 – 650 kg and were weighed immediately prior to the start of each trial to ensure
accurate dosing. All horses gained weight over the course of the study, with a mean
weight gain of 21.6 ± 9.6 kg. This was attributed to access to lush forage as the study took
place between April and June when the horses were housed on green pasture. All
procedures in this study were approved by the Institutional Animal Care and Use
Committee at Purdue University.

3.3.2 Drug Administration
A 0.5 mg/kg dosage of KT was used for IV, IM (30 mg/ml)a and PO (10 mg/tablet)b
administration, with a 2 week washout period between each trial. The 0.5 mg/kg dose of
KT was equivalent to a KT dose of 0.34 mg/kg. Injectable drug doses were rounded up to
the nearest 0.1 mL; oral doses were rounded up to the nearest whole tablet (10 mg). The
washout period was selected to exceed the anticipated elimination half-time by at least
10 times. For the first 24 h of each trial, the horses were housed in box stalls with free
access to grass hay, alfalfa hay, and water. The horses were not fasted before or after PO
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administration in order to mimic clinical administration. After the first 24 h of each trial
and during the washout period the horses were housed on pasture.
Intravenous jugular catheters were aseptically placed the night before the start of
each trial; horses undergoing IV drug administration had a catheter placed in each jugular
vein. The catheter used to deliver the KT was removed after drug administration; the
contralateral catheter was used for all blood collections. Intramuscular injection of KT was
performed in the neck muscle opposite that of the jugular catheter. The oral dose of KT
was delivered via nasogastric tube; the tablets were first dissolved in 60 mL of water,
added to the nasogastric tube, and then followed by 3 L of water to ensure complete
delivery of the drug.
Heparinized blood samples were collected from the jugular vein catheter
immediately prior to drug administration (t=0) and at 5, 10, 15, 20, 30, 45, 60, 90 min and
2, 3, 4, 6, 8, 10, 12, 24 h and 48 h after drug administration. Plasma was harvested by
centrifugation at 1,300 g for 5 minutes within 6 h of collection and stored at -80oC until
analyzed. Ketorolac tromethamine is stable in plasma for at least 30 days when stored at
-20oC 19 or -80oC 20.

3.3.3 Adverse Effects
Horses were continually monitored during the first 12 h of each trial and complete
physical examinations were performed at t=0, 4, 12, 24 and 48 h. A CBCc and SBAd were
performed at t=0 and t=24 h. Subjective assessments were made regarding changes in
behavior, appetite, and fecal consistency, as well as evidence of inflammation at the IM
injection site (characterized by the presence of heat, swelling, or pain).
3.3.4 Sample Analysis
Plasma samples were prepared as described prior to high performance liquid
chromatography (HPLC) tandem mass spectrometry (MS-MS) analysis20,21. Briefly, an
internal standard (IS) solution containing 50 uL etodolac (500 ng/mL in 50% water:50%
acetonitrile) was added to 200 μL plasma and vortexed.22 Protein precipitation was
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performed by adding 800 μL of a solution of 0.1% formic acid in acetonitrile. The mixture
was vortexed and then centrifuged at 12,000 g for 5 minutes. Aliquots of 500 μL were
transferred to HPLC vials with 10 μL submitted for HPLC/MS-MS analysis.
Ketorolac tromethamine plasma levels were quantitated by HPLC-MS-MS.
Separation was performed on an Agilent Rapid Res 1200 HPLC system using an Agilent
Zorbax XDB-C18 (2.1 x 50 mm, 3.5 μm) column.e Mobile phase A was H20 with 0.1%
formic acid and mobile phase B was ACN with 0.1% formic acid. A linear gradient elution
was used as follows: initial conditions 35% B; 0 - 8 min: gradient to 70% B; 8 – 8.5 min:
gradient to 90% B; 8.5 – 9.5 min: gradient held 90% B. During compound elution, a flow
rate of 0.4 mL/min was used. Column re-equilibration was 9.5 – 10.5 min: gradient to 35%
B; 10.5 – 13.5 min: gradient held 35% B. During re-equilibration, flow rate was increased
to 0.6 mL/min and column flow was diverted to waste. Retention time for KT was 3.2
minutes and for etodolac was 6.9 minutes.
Analytes were quantified using MS/MS utilizing an Agilent 6460 Triple Quadrupole
mass spectrometer with electrospray ionization (ESI).f Quantitation was based on
Multiple Reaction Monitoring (MRM). For KT, ESI positive mode was used with a transition
of 256.1 to 104.9 and a collision energy (CE) of 18 V. For etodolac, ESI negative mode was
used with a transition of 286.1 to 212.1 and a CE of 20 V. Both compounds used a
fragmentor energy of 125 V and a dwell time of 300 ms. Source parameters were as
follows: nitrogen gas temperature = 350°C and flow rate = 9 L/min, nebulizer pressure =
40 psi, sheath gas temperature = 250°C, sheath gas flow rate = 7 L/min, and capillary
potential = 3500 V. All data were collected and analyzed with Agilent MassHunter B.03
software. Quantitation was based on a 6 point standard curve, with KT concentrations
ranging from 2.5 to 5,000 ng/mL, using a diluent of acetonitrile and water (1:1, v/v).
Standard curves were fit to a quadratic function, with a 1/x curve fit weighting.
Correlation coefficients > 0.9997 were obtained. Curves were used if the standard
concentration accuracy for each point was between 95 – 105%. Responses for KT were
normalized against the internal standard (RR = response ratio).
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The limit of quantitation was 1.2 ng/mL and the limit of detection was 0.5 ng/ml,
as defined as a signal-to-noise ratio (RMS) of 10:1 and 3:1, respectively, determined using
authentic standards. Matrix effects and extraction recoveries were assessed using the
approach detailed by Trufelli et al.23 Matrix effects were determined by ratioing the RR in
matrix-matched standards to the RR in neat standards. The matrix effect was determined
at 2.5 (low), 250 (middle), and 5,000 (high) ng/mL, which were 122%, 127%, and 99.2%,
respectively (n=6). Extraction efficiencies were determined by ratioing the RR in preextraction spiked plasma to matrix-matched standards. The extraction efficiencies were
determined at 2.5 (low), 250 (middle), and 5,000 (high) ng/mL, which were 84.3%, 89.0%,
and 123%, respectively (n=6). Since no significant matrix effects or extraction efficiencies
were observed, calibrants and control samples were prepared using a solvent of
acetonitrile and water (1:1, v/v). At 2.5 (low), 250 (middle), and 5,000 (high) ng/mL, the
precision (relative standard deviation, RSD) of the standard curves were 7.0%, 3.7%, and
1.7%, respectively (n=6). Based on a 100 ng/mL control sample, the intraday assay
precision RSD ranged from 3.6% - 13.1%, and the interday precision (n=7) was 8.3%. The
intraday accuracy RSD ranged from 95.8% - 103.9%, and the interday accuracy (n=7) was
98.8%.

3.3.5 Pharmacokinetic Analysis
Pharmacokinetics were characterized using standard compartmental and
noncompartmental methods and a software program.e A variety of weighting schemes
were examined and the best model fit (inverse of concentration squared) was determined
using Akaike’s Information Criterion and the smallest sum of squared residuals.
Compartmental pharmacokinetic variables were attempted to be obtained for IV,
IM and PO data from each horse by fitting the plasma KT concentration-time data to a
two and three-compartment open model using various weighting schemes. Compartment
models could not be satisfactorily fit to IV data for the majority of horses and to IM and
PO data for any horse. Non-compartmental analysis for IV, IM and PO data from each
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horse were fit using the last three or more data points from the semilog plasma
concentration-time curve to calculate the elimination rate constant (λZ, slope of the
terminal linear phase). The area under the curve (AUC∞) and the area under the first
moment curve (AUMC∞) were calculated for each horse and treatment from the KT
concentration-time relationship using the trapezoidal method, with the area from the last
time point extrapolated to infinity using the last measured plasma KT concentration and
λZ. The elimination half-life was calculated as 0.693/λZ. Mean residence time (MRT) was
calculated from the ratio of AUMC∞ to AUC∞. Total plasma clearance (Clp) was calculated
as dose/AUC∞. The apparent steady-state volume of distribution (Vd(ss)) was calculated as
dose×AUMC∞/AUC∞2. Mean absorption time (MAT) for IM or PO administration was
calculated as MATIM = MRTIM – MRTIV or MRTPO – MRTIV. Bioavailability was determined
by dividing the IM or PO AUC∞ by the IV AUC∞ and multiplying by 100.

3.3.6 Statistical Analysis
Significance was set at p < 0.05. Data was expressed as mean ± SD and plasma
concentration-time data was presented in a semi-logarithmic graph. A mixed model
analysis of variance (ANOVA) with repeated measures was used to evaluate the CBC and
SBA data in order to account for the crossover experimental design.f

3.4

Results

3.4.1 Pharmacokinetics
The plasma concentration-time relationship of KT following a single 0.5 mg/kg IV
dose is depicted in Figure 1 and relevant pharmacokinetic variables are summarized in
Tables 2-1, 2-2, and 2-3. Plasma KT concentration was below the limit of detection for all
horses and routes of administration at 48 h. Mean total plasma clearance (Clp) was rapid
at 8.4 (mL/min)/kg and the estimated mean volume of distribution at steady state (Vd(ss))
was 0.77 L/kg.
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The plasma concentration-time relationship of KT following 0.5 mg/kg IM or PO
dosing is depicted in Figure 1 and relevant pharmacokinetic variables are summarized in
Table 1. The mean observed time to maximum concentration (t max) after IM or PO
administration was 25 and 19 min, respectively, indicating rapid absorption. The observed
peak mean plasma concentrations (Cmax) after IM or PO administration were 0.58 and 0.31
µg/mL, respectively. The MRT was 2.0 h for IV, 2.6 h for IM and 7.1 h for PO administration.
Calculated mean bioavailability (F) of KT after IM and PO delivery was 71% and 57%,
respectively.

3.4.2 Adverse Effects
There were no significant changes in the physical examination or CBC of any horse
during any trial period (Table 2-4). No subjective changes were noted in the behavior,
appetite, or fecal consistency of any horse during any trial period. While none of the IM
injection sites showed any clinical evidence of pain or inflammation, plasma creatinine
kinase activity was increased at 24 h after IM injection (p = 0.012). The mean CK value
pre-injection was 136 ± 34 IU/L versus a post-injection CK value of 162 ± 50 IU/L (Table 25).
3.5

Discussion

Similar to other species, the pharmacokinetic profile of KT after IV administration
was characterized by a low volume of distribution and rapid clearance from the plasma
compartment.23, 24 The drug was rapidly absorbed after IM and PO administration and no
clinical adverse effects were observed after single dose administration.
Mean total plasma clearance of KT was higher in the current study (8.4 mL/min/kg)
than previously reported for horses by Plånborg et al. (2.8 mL/min/kg) and Ferraresi et al.
(5.6 mL/min/kg).11,12 Differences in drug clearance after IV administration of a water
soluble drug such as KT is primarily due to species differences in the rate of hepatic KT
metabolism or renal blood flow, as KT is primarily metabolized by the liver to form
glucuronide conjugates and excreted by the kidneys.19 Species differences in urine pH
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may impact plasma clearance of acidic drugs such as KT, as alkaline urine has the potential
to ion trap KT and thereby prevent reabsorption; however, this is considered an unlikely
reason for the high clearance in horses, as KT has a pKa value of 3.5 which indicates
effectively full dissociation even in acidic urine (pH = 5.5). Moreover, clearance of KT after
IV administration is variable in ruminants that typically have an alkaline urine, being 12.4
(mL/min)/kg in adult sheep,24 8.8 (mL/min)/kg in adult goats,23 but only 0.8 (mL/min)/kg
in calves.25 Differences in drug clearance may also be due to differences in plasma protein
binding between species, as small changes in binding percentage for highly bound drugs
such as KT can have a large impact on drug availability for hepatic metabolism or urinary
excretion.25 Additional studies to determine the rate of hepatic metabolism are indicated
to confirm the supposition that rapid hepatic metabolism is the reason for the high
plasma clearance of KT in horses.
It is not clear why Plånborg et al. found KT to have a much slower clearance than
that reported in our study, but only 3 horses were used in that study to estimate
clearance, and their assay was able to detect KT only up to 3 h post administration,11
which was probably too short a time interval to provide an accurate estimate of clearance.
The colts in the Ferraresi et al. study received acepromazine, detomidine, ketamine, and
diazepam in addition to KT before undergoing general anesthesia with isoflurane;
clearance of KT is expected to be decreased in horses receiving these drugs because of
drug-induced decreases in cardiac output, mean arterial pressure, renal blood flow, and
core body temperature.26-28 Given the rapid clearance of KT in the horse, the most useful
application of the drug in horses is likely to be as a short term continuous rate IV infusion
(CRI) or oral administration in horses with normal gastrointestinal motility. While there
are no reports in the veterinary literature, CRI of NSAIDs has been described in human
medicine for treatment of fever or pain due to surgery or cancer.29-31 When administered
as a CRI in humans, KT has been shown to be safe and effective at providing analgesia and
reducing the use of opiates.32, 33
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The mean Vd(ss) of KT in the current study (0.77 L/kg; median 0.49 L/kg) was similar
to that for other NSAIDs 19 and was most likely due to a moderately high degree of plasma
protein binding. While not specifically evaluated in the current study, Ferraresi et al.
reported a plasma binding of 76% in horse plasma.12 Plasma binding of KT is 72.0% in
mice,19 92.1% in rats, 1998.9% in dogs,17 and 99.2% in humans.19
The mean plasma elimination t1/2 of KT in this study following IV administration
was 8.7 h (median 5.8 h). For comparison, sheep have a much shorter t1/2 (18 min) after
IV administration,24 whereas studies in dogs,18 calves,25 and the 1994 study in horses11
reported an elimination half-life similar to that observed in humans of approximately 4 to
6 h.
The pharmacokinetic profile of KT after IM injection could not be adequately
characterized using a compartmental model; consequently, non-compartmental analysis
was performed. Ketorolac tromethamine was rapidly absorbed after IM injection in
horses, with a mean absorption time of 36 min (95% confidence interval for mean
absorption time of -5.5 to 6.7 h) that was similar to that reported in sheep (11 min)24 and
humans (46 min).34
Oral administration of KT resulted in a tmax of 19 min in horses, which is shorter
than the tmax in dogs (51 min)18 and humans (53 min).34 While the oral pharmacokinetics
of KT have been evaluated in goats and calves, it is difficult to compare oral drug
administration in ruminants vs. non-ruminant animals given the vast difference in drug
absorption resulting in delayed tmax (6.5 h in calves and 8.9 h in goats).23,25 The differences
in tmax between horses and dogs may be related to method of administration; the tablets
in the current study were dissolved in 60 mL of water prior to administration, and then
followed by 3 L of water which may have facilitated gastric emptying and therefore a
faster rate of delivery to the small intestine. The oral formulation given to dogs was
reported to be a capsule, which may have delayed drug absorption.18 Ketorolac
tromethamine was administered via nasogastric tube in this study in order to ensure the
horse received the entire drug amount and permit accurate estimation of oral
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bioavailability; however, this method of administration did not permit evaluation of the
potential influence of buccal drug absorption. While in a clinical setting KT would likely be
given via oral dose syringe, given the moderate oral bioavailability of KT found in this
study, and all other studies in a variety of species,18,19,25 it is unlikely that buccal
absorption would have had an impact on the plasma KT concentration-time profile. Per
os administration of drugs is not usually accompanied by water, and delivery likely results
in partial loss of drug. Thus, intragastric administration of KT may have falsely increased
oral bioavailability in this study. Interestingly, the plasma concentration-time relationship
after oral KT administration appeared to be biphasic, with a slightly higher plasma KT
concentration present than anticipated from approximately 4 to 12 h after
administration. A more exaggerated pattern has been observed in dogs administered KT
intravenously,17 leading to speculation that enterohepatic cycling of KT may have been
present.
As reported in humans and other species,18 19,23,25,34 the mean bioavailability of KT
after both IM and PO administration was moderate at 71% and 57%, respectively. This is
similar to the IM bioavailability previously reported in horses (69%).11
While the target plasma concentration of KT for effective analgesia in horses is not
known, an EC50 of 0.37 µg/mL for plasma KT concentration has been calculated for
humans using pharmacodynamic modeling.35 Interestingly, oral administration of KT
failed to achieve a mean plasma KT concentration of 0.37 µg/mL, and IM administration
resulted in plasma KT concentration exceeding 0.37 µg/mL for less than 1 h.
Despite the extensive literature on analgesic properties of KT in humans,
veterinary studies are sparse. Only one analgesic trial has been performed in horses,
when 6 colts undergoing elective castration received KT pre-operatively (0.5 mg/kg IV).12
All colts experienced adequate analgesia, as determined by a visual analog score,
although there was no untreated control group and investigators were therefore not
masked to treatment.12 Several studies have evaluated the clinical efficacy of KT in
providing post-operative analgesia in dogs. In a randomized controlled trial, KT given at a
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dose of 0.5 mg/kg IM was as effective as flunixin meglumine (1.0 mg/kg IM) and superior
to both butorphanol (0.4 mg/kg IM) and oxymorphone (0.05 mg/kg IM) in providing
consistent post-operative analgesia.16 Similar findings were observed in a clinical trial
during which 15 dogs received KT (0.5 mg/kg IV) for analgesia associated with elective
castration, though no control group was used in that study

17.

Given the diversity of

individual pain sensitivity and the variety of painful medical conditions, determining the
effective therapeutic concentration of a drug is difficult, even when patients can verbally
communicate their pain level. Furthermore, the target therapeutic concentration of a
drug is likely to vary among species. Therefore, the appropriate dosage of a drug must be
based on attaining the plasma concentration that has been shown to be both effective
and safe.
While no adverse effects were noted in the current study, NSAID use in all species
is associated with damage to the renal medulla and gastrointestinal mucosa due to
inhibition of prostaglandin E2 and vasoconstriction. The safety of KT has been evaluated
extensively in humans with mixed results. While several studies report that the risk of
adverse effects is not higher than other NSAIDs,13,14 other studies have cited KT has having
a higher relative risk of upper gastrointestinal bleeding in comparison to other human
NSAIDs.36 The risk of adverse effects in humans has been shown to be increased in certain
patients with preexisting conditions such as renal or gastrointestinal disease,
coagulopathy, or those receiving concurrent administration of other NSAIDs. Given these
potential risks in the human population, use of KT in the United States is restricted to no
more than 5 days of treatment 37. While no adverse effects have been noted in any of the
previous veterinary single-dose pharmacokinetic studies, only one study has specifically
evaluated the safety of multiple doses of KT. In this study, no difference in adverse effects
was found between KT and flunixin meglumine in dogs after 3 doses of either drug
administered 6 h apart.16 Given the potentially severe adverse effects of NSAIDs in horses,
the safety of KT must be evaluated further.
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The increase in CK values noted after IM injection may or may not be clinically
relevant. Creatine kinase is a sensitive indicator of muscle damage; a small amount of
muscle damage can result in a detectable elevation in CK and does not necessarily result
in clinically detectable pain or inflammation.38 None of the horses experienced clinical
evidence of injection site reaction in this study or had a CK value that was outside of the
reference range; however, the post-injection samples were collected 24 h after injection
and CK activity peaks 6-12 h after muscle injury.39 While the KT administered to horses in
this study was formulated for IM use in humans and is commonly used without significant
adverse effects, the potential for muscle damage may become apparent with repeated or
prolonged dosing in horses.

3.6

Conclusion

In conclusion, the pharmacokinetic profile indicates rapid absorption when KT is
administered orally or by IM injection in healthy adult horses with no obvious adverse
effects after a single 0.5 mg/kg dosage. Further studies are necessary to evaluate the
analgesic and anti-inflammatory properties of a CRI of KT in the horse, as well as the drug’s
safety profile when administered as a CRI.
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d
Johnson & Johnson Vitros 5,1 FS Chemistry Analyzer, Holliston, MA
e
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f
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g
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Table 3-1: Non-compartmental pharmacokinetic parameters and body weight for ketorolac tromethamine in healthy adult horses
(n=9) following a single (0.5 mg/kg) intravenous dose.
Intravenous
Horse
Variable
1
2
3
4
5
6
7
8
9
Body weight (kg)
565
511
546
585
541
564
461
492
634
C0 (µg/mL)
3.48 1.46 1.06 3.50 3.65 2.77 5.84 1.73 3.78
λz (h-1)
0.049 0.549 0.555 0.051 0.032 0.120 0.483 0.045 0.171
t1/2 (h)
14.1
1.3
1.2
13.5 21.9
5.8
1.4
15.4
4.1
AUC∞ (h×µg/mL)
0.984 0.437 0.204 0.824 0.697 0.824 0.515 0.628 0.804
2
AUMC∞ (h ×µg/mL) 3.171 0.196 0.075 2.131 3.614 0.802 0.095 2.641 0.577
MRT (h)
3.2
0.4
0.4
2.6
5.2
1.0
0.2
4.2
0.7
Clp ({ml/min}/kg)
4.8
9.7
22.3
5.9
6.5
5.7
7.5
6.5
6.6
Vd(ss) (L/kg)
0.93 0.26 0.49 0.92 2.01 0.33 0.08 1.65 0.28

Mean
SD CV (%)
544
52
9
3.03 1.47
49
0.228 0.231 101
8.7
7.6
87
0.657 0.240
37
1.478 1.415
96
2.0
1.9
94
8.4
5.4
64
0.77 0.67
87

C0 = plasma concentration at time = 0 h; λz = elimination rate constant; t1/2 = elimination half-life; AUC∞ = area under the plasma concentration vs. time curve;
AUMC∞ = area under the first moment curve; MRT = mean residence time; Clp = Plasma clearance; Vd(ss) = Volume of distribution at steady state; SD = standard
deviation; CV = coefficient of variation.
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Table 3-2: Non-compartmental pharmacokinetic parameters and body weight for ketorolac tromethamine in healthy adult horses
(n=9) following a single (0.5 mg/kg) intramuscular dose.
Intramuscular
Horse
Variable
1
2
3
4
5
6
7
8
9
Body weight (kg)
554
504
578
563
529
579
460
493
650
Cmax (µg/mL)
0.31 0.70 0.67 0.52 1.55 0.39 0.37 0.40 0.29
tmax (h)
0.50 0.25 0.17 0.25 0.17 0.75 0.33 0.33 1.00
-1
λz (h )
0.238 0.057 0.080 0.430 0.204 0.055 0.065 0.178 0.060
t1/2 (h)
2.9
12.1
8.6
1.6
3.4
12.5 10.7
3.9
11.6
AUC∞ (h×µg/mL)
0.621 0.836 0.633 0.659 1.019 0.662 0.647 0.488 0.626
AUMC∞ (h2×µg/mL) 1.160 2.766 1.354 0.828 1.257 2.313 3.429 0.676 2.212
MRT (h)
1.9
3.3
2.1
1.3
1.3
3.5
5.3
1.4
3.5
MAT (h)
-1.4
2.9
1.8
-1.3
-3.9
2.5
5.1
-2.8
2.8
F (%)
65
84
64
68
110
67
65
52
63

Mean
SD CV (%)
546
57
10
0.58 0.39
68
0.42 0.29
69
0.152 0.126
83
7.5
4.5
60
0.688 0.152
22
1.777 0.944
53
2.6
1.4
53
0.6
3.1
489
71
17
24

Cmax = maximum plasma concentration; tmax = time to observed maximum plasma concentration; λz = elimination rate constant; t1/2 = elimination half-life; AUC∞
= area under the plasma concentration vs. time curve; AUMC∞ = area under the first moment curve; MRT, mean residence time; MAT = mean absorption time;
F = percent bioavailability. SD = standard deviation; CV = coefficient of variation.
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Table 3-3: Non-compartmental pharmacokinetic parameters and body weight for ketorolac tromethamine in healthy adult horses
(n=9) following a single (0.5 mg/kg) oral dose.
Oral
Horse
Variable
1
2
3
4
5
6
7
8
9
Body weight (kg)
572
491
581
599
506
584
467
477
662
Cmax (µg/mL)
0.22 0.15 0.46 0.32 0.12 0.30 0.24 0.79 0.23
tmax (h)
0.25 0.33 0.25 0.25 0.50 0.17 0.17 0.50 0.33
-1
λz (h )
0.083 0.133 0.152 0.077 0.100 0.098 0.092 0.100 0.117
t1/2 (h)
8.3
5.2
4.6
9.0
7.0
7.1
7.5
6.9
5.9
AUC∞ (h×µg/mL)
0.576 0.313 0.775 0.562 0.611 0.424 0.379 0.931 0.342
AUMC∞ (h2×µg/mL) 5.997 1.954 3.815 5.491 5.447 1.923 2.877 4.840 2.124
MRT (h)
10.4
6.2
4.9
9.8
8.9
4.5
7.6
5.2
6.2
MAT (h)
7.2
5.8
4.6
7.2
3.7
3.6
7.4
1.0
5.5
F (%)
60
31
78
58
66
43
38
99
35

Mean
SD CV (%)
549
66
12
0.31 0.20
64
0.31 0.13
41
0.106 0.024
23
6.8
1.4
21
0.546 0.208
38
3.830 1.661
43
7.1
2.2
31
5.1
2.1
42
57
22
40

Cmax = maximum plasma concentration; tmax = time to observed maximum plasma concentration; λz = elimination rate constant; t1/2 = elimination half-life; AUC∞
= area under the plasma concentration vs. time curve; AUMC∞ = area under the first moment curve; MRT, mean residence time; MAT = mean absorption time;
F = percent bioavailability. SD = standard deviation; CV = coefficient of variation.
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Table 3-4: Mean ± SD of complete blood count parameters for intravenous (IV), intramuscular (IM) and oral (PO) before (pre) and 24
hours after (post) administration of ketorolac tromethamine (0.5 mg/kg) in 9 adult horses.
IV pre

IV post

IM pre

IM post

PO pre

PO post

Variable

Units

Total Plasma Protein
RBC
Hematocrit

g/dl
M/µl
%

Reference
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
range
5.7-8.1
6.9
0.4
7.0
0.3
6.8
0.3
6.9
0.3
6.9
0.5
7.0
0.4
6.0-12.0
8.2
0.9
7.8
0.9
8.4
0.9
8.3
1.0
8.2
0.8
7.9
0.8
35.0-50.0 40.7 4.0 38.8 3.7 41.9 4.1 40.9 4.1 40.6 3.5 39.3 2.7

Hemoglobin

g/dl

11.0-19.0

13.7

1.3

13.1

1.4

14.2

1.5

13.9

1.6

13.7

1.2

13.3

0.9

MCV

fL

35.0-55.0

49.9

2.2

50.0

2.2

49.8

2.0

49.5

1.6

49.8

2.2

49.9

2.3

MCHC

g/dl

30.0-36.0

33.7

0.5

33.8

0.7

33.8

0.5

33.9

0.8

33.8

0.6

33.9

0.4

White blood cells

K/µl

6.0-12.0

7.6

2.0

7.9

2.5

7.2

1.4

7.8

1.5

7.6

2.2

7.4

2.3

Neutrophil

K/µl

3.0-7.0

5.0

2.3

5.2

2.7

4.5

1.2

4.9

1.4

5.0

1.9

4.7

1.6

Lymphocyte

K/µl

1.5-5.5

2.3

0.6

2.4

0.9

2.5

0.9

2.5

0.5

2.3

0.7

2.3

1.0

Monocyte

K/µl

0.05-0.80

0.2

0.2

0.2

0.1

0.2

0.1

0.3

0.2

0.1

0.1

0.2

0.1

Eosinophil

K/µl

0.0-0.4

0.2

0.2

0.2

0.2

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1
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Table 3-5: Mean ± SD of serum biochemical analysis parameters for intravenous (IV), intramuscular (IM) and oral (PO) before (pre)
and 24 hours after (post) administration of ketorolac tromethamine (0.5 mg/kg) in 9 adult horses.
IV pre
Variable

Units

Glucose
BUN
Creatinine
Phosphorus
Calcium
Sodium
Potassium
Chloride
Carbon
dioxide
Anion Gap
Total Protein
Albumin
Globulin
AST
ALP
GGT
Bilirubin
Magnesium
Creatinine
Kinase

mg/dl
mg/dl
mg/dl
mg/dl
mg/dl
mmol/L
mmol/L
mmol/L

Reference
range
73-124
8.0-27
0.6-1.8
2.0-5.7
10.7-13.4
132-144
2.7-4.8
94-103

mmol/L

IV post

IM pre

IM post

PO pre

PO post

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

98.3
18.4
1.0
3.9
12.2
138.2
3.5
100.1

6.2
3.5
0.1
0.4
0.8
2.4
0.7
2.0

98.8
17.3
1.0
3.8
12.1
138.7
3.5
99.6

9.6
4.4
0.2
0.6
0.7
1.7
0.4
1.7

96.6
18.2
1.0
3.8
11.0
138.7
3.6
100.1

7.0
4.4
0.1
0.5
3.5
2.1
0.6
2.2

95.1
18.3
1.0
3.7
12.2
138.0
3.5
99.0

4.8
4.9
0.1
0.8
0.4
2.5
0.7
2.0

96.8
18.8
1.0
3.6
12.2
138.3
3.5
99.8

10.0
3.8
0.1
0.5
0.6
1.4
0.5
2.3

98.8
18.0
1.0
3.7
12.3
138.7
3.4
98.9

9.7
4.3
0.1
0.5
0.5
1.4
0.6
1.3

23-31

29.3

1.4

29.8

2.0

29.7

1.8

29.6

1.6

29.7

1.9

29.9

2.0

mmol/L
g/dl
g/dl
g/dl
IU/L
IU/L
IU/L
mg/dl
mg/dl

12.0-20
4.7-7.5
2.5-3.8
2.2-3.8
206-810
109-331
12.0-46
0.10-2.6
1.6-2.7

12.3
6.7
3.0
3.7
379.9
153.8
31.7
1.5
1.6

1.4
0.4
0.2
0.4
101.8
74.5
9.4
0.3
0.2

12.8
6.6
3.0
3.7
368.2
156.2
32.3
1.7
1.7

1.8
0.3
0.1
0.3
75.0
76.6
9.7
0.4
0.2

12.5
6.6
3.0
3.7
363.2
144.2
31.7
1.3
1.7

1.4
0.4
0.1
0.3
73.2
49.4
8.9
0.4
0.2

12.9
6.7
3.0
3.7
376.3
148.3
32.8
1.7
1.7

1.8
0.4
0.2
0.3
69.5
48.9
8.1
0.6
0.2

12.4
6.6
3.0
3.7
370.9
152.1
32.7
1.4
1.7

2.4
0.5
0.2
0.3
48.3
72.2
10.3
0.3
0.1

13.3
6.8
3.0
3.7
369.9
156.2
33.3
1.7
1.7

1.5
0.4
0.2
0.2
43.9
77.1
10.3
0.5
0.2

IU/L

88-453

161.4

67.3

159.0

40.8

135.7

33.5

162.1

50.2

135.8

39.2

153.9

65.2
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Figure 3-1: Concentration vs. time curve for ketorolac tromethamine (0.5 mg/kg) in 9 adult horses after intravenous (IV), intramuscular
(IM) and oral (PO) administration
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CHAPTER 4.

CONCLUSIONS AND FUTURE DIRECTIONS

Ultimately, KT needs to be evaluated for its anti-inflammatory and analgesic
efficacy, as well as safety, before being used in horses in a clinical setting. Specifically, KT
should be compared to the NSAIDs currently approved for use in horses, including the
nonspecific COX inhibitors flunixin meglumine and phenylbutazone, as well as the COX-2
selective inhibitor firocoxib.
The anti-inflammatory properties of KT have not yet been evaluated in horses.
Initial studies may be performed in vitro and then in vivo using established equine models
of gram negative sepsis, or endotoxemia.1–6 Currently, we have obtained funding to study
the anti-inflammatory properties of KT. Monocytes will be isolated and cultured from
healthy horses and then exposed to LPS in vitro as previously described4 and then exposed
to KT, a positive control (flunixin meglumine) or negative control. Cytokine (TNFα, IL-6,
and IL-8) and eicosanoid (PGE2 and TXB2) production will be measured as a measurement
of anti-inflammatory properties.
In order to evaluate KT’s efficacy as an analgesic, a standardized pain model should
be used before implementing a clinical trial. Foreman et al. have developed a model of
reversible lameness that they have used to evaluate the analgesic efficacy of several
NSAIDs.7,8 By using a standardized model, both the dose and efficacy of KT can be
established.
In human medicine, KT is often used as a CRI to provide analgesia in certain
situations such as postoperatively or for cancer pain.9–16 Other NSAIDs, such as
diclofenac,17,18 ketoprofen,19–21 or ibuprofen22 have also been used in human clinical
patients. While postoperative use of butorphanol23 and lidocaine24 CRIs have previously
been evaluated in clinical equine patients, there has been no published report of an NSAID
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given as a CRI in veterinary medicine. One future goal of this research is to explore
the possibility that KT can be employed as a CRI to provide superior, continuous analgesia
to horses with a high degree of pain, such as postoperatively.
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